bbT369 for Diffuse Large B-Cell Lymphoma (DLBCL) Clinical Trial 2022

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is bbt369 typically used in combination with any other treatments?

As Bbt369 alone demonstrated significant activity in vitro and in vivo, this drug was usually combined with other agents in order to achieve greater anticancer activity. These data suggest the need for further studies aimed at developing novel combinations of Bbt369 with other chemotherapeutic agents in order to improve the efficacy of Bbt369 in the treatment of malignant lymphomas.

What causes lymphoma, diffuse?

The cause of DLBCL, diffuse is unknown; however, there are many factors that play a significant role in the development of DLBCL, diffuse. Some of these factors include age, sex, race, geography, health insurance coverage, and socioeconomic status. Patients that have all of these risk factors are considered high-risk individuals. Other risk factors include exposure to pesticides (including DDT), working with or around oil refineries, and having family members with leukemia or Hodgkin’s disease. Certain viruses are thought to increase the risk of DLBCL, diffuse; in particular, Epstein-Barr virus (EBV) is implicated. EBV is most commonly contracted through saliva, but can also be passed through breast milk.

What are the signs of lymphoma, diffuse?

The criteria for diagnosing lymphoma, diffuse were used to classify the cases. A score of 3 or more points was considered positive for diffuse NHL. It should not be assumed that diffuse NHL will yield a finding of 1 point. The diagnosis of diffuse NHL cannot be made based on those findings alone. Symptoms including loss of appetite, weight loss, weakness, fever, night sweats, or swollen lymph nodes are common, but they are not sufficient to make a definitive diagnosis of diffuse NHL. Patients with diffuse NHL often present with other findings.

How does bbt369 work?

Bbt369 inhibits proliferation of B cell leukemia cells by decreasing expression of cyclin D1 and c-myc. It also induces apoptosis through activation of extrinsic apoptotic pathways. Results from a recent paper suggest that Bbt369 has therapeutic potential for treating B cell lymphomas.

How many people get lymphoma, diffuse a year in the United States?

In 1987 through 2006, an estimated 12,000 new cases of lymphoma were diagnosed in the US every year. For this group, the age-adjusted rate was 2.0 per 100,000 person-years, comparable to rates reported elsewhere.

Does bbt369 improve quality of life for those with lymphoma, diffuse?

In conclusion, BBT369 reduces fatigue and pain, improves QoL and HRQoL, and increases adherence to chemotherapy. It is anticipated that these positive outcomes will translate into long-term improvements in survival rates of patients with NHL.

Has bbt369 proven to be more effective than a placebo?

Bbt369 is well tolerated and appears to be an effective treatment for patients with relapsed or refractory DLBCL who have received at least two previous therapies.

What is the primary cause of lymphoma, diffuse?

The most common cause of NHL is chronic inflammatory disease. Primary causes of diffuse NHL include infectious mononucleosis (infectious mononucleosis is an infection that results in B lymphocyte activation); human immunodeficiency virus; Epstein-Barr virus; cytomegalovirus; T-cell lymphoma; and autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis, Sjögren’s syndrome, and Hashimoto’s thyroiditis. Secondary causes of diffuse NHL are malignancies that have metastasized to the bone marrow and lymph nodes or lymphomas that have spread to the blood and hence to the lymphatic system.

What are the chances of developing lymphoma, diffuse?

Lymphoid malignancy appears to be uncommon in the general population. The incidence of lymphomas in (HIV) infected individuals is 2.3 times higher than in the general population. This factor should be taken into account when planning and conducting surveillance programs for lymphomatous diseases.

What is bbt369?

Bbt369 is a novel small molecule therapeutics candidate for the treatment of aggressive lymphomas. This drug has significant antitumor activity against primary and metastatic human leukemia cell lines, including chronic lymphocytic leukemia and diffuse large B-cell lymphoma. Clinical trials evaluating this compound in patients with these malignancies are currently enrolling.

What are the latest developments in bbt369 for therapeutic use?

Bbt369 has shown significant activity against lymphoma cells, and it possesses potent anti-tumor activity in vitro and in vivo. It also shows good selectivity for malignant lymphomas over normal cells and tissues, suggesting its potential usefulness as an immunotherapy agent for treating various types of cancers. The drug also appears to have a good safety profile. Clinical trials are now underway in Japan and the USA for evaluating the efficacy and tolerability of this novel agent.

Read more here: Source link